Tag Archives: thyroid

Thyroid cancer: A worrying gastrointestinal symptom indicating your risk of the disease

Thyroid cancer: A worrying gastrointestinal symptom indicating your risk of the disease

Thyroid cancer is a rare type of cancer that affects the thyroid gland, a small gland at the base of the neck. The most common symptom of cancer of the thyroid is a painless lump or swelling that develops in the neck. Other symptoms only tend to occur after the condition has reached an advanced stage including this gastrointestinal symptom to be aware of.

In a study published in Karger, diarrhoea as an initial presentation in patients with thyroid cancer was analysed.

Tumoral secretion of various molecular factors, such as calcitonin, can cause diarrhoea in patients with medullary thyroid cancer, reported the study.

It added: “Two patients with elevated calcitonin had no diarrhoea.

“The link between tumour humoral secretion and diarrhoea is not well established in patients with thyroid cancer.

“Diarrhoea is more common in patients with metastatic disease and improves after resection of the tumour.

“Diarrhoea may result from elevated circulating levels of calcitonin or other substances, such as prostaglandins or serotonin.

“Other proposed mechanisms include decreased absorption in the colon secondary to gastrointestinal motor disturbances.

“In conclusion, thyroid cancer should be considered when evaluating chronic diarrhoea.”

Popular drink shown to alleviate arthritis [TIPS]
Diabetes type 2: Three main indicators [INSIGHT]
How to live longer: Eat small servings of fruit [ADVICE]

Chronic diarrhoea is when symptoms last for more than four to six weeks.

One case study found a 36-year-old male with no notable medical history who started with diarrhoea with three to four stools a day, some during the night, without blood, mucus or pus.

He had no abdominal pain, nausea, vomiting or fever.

On physical examination, his abdomen was soft, non-tender and with no palpable masses or organomegaly.

A broader study was ordered including an abdominal ultrasound.

A CT scan of the chest and abdomen was performed with the scan showing liver nodules, osteoblastic bone lesions and a thyroid nodule, all of which is indicative of a neuroendocrine tumour.

Each year, around 2,700 people are diagnosed with thyroid cancer in the UK.

It’s most common in people aged 35 to 39 years and in those aged 70 years or over.

Women are two to three times more likely to develop thyroid cancer than men.

The reason for this is unclear but it may be a result of the hormonal changes associated with the female reproductive system.

Author: Jessica Knibbs
Read more here >>> Daily Express :: Health
Read More

Thyroid cancer: The lesser-known warning sign of your risk found in the ear

Thyroid cancer: The lesser-known warning sign of your risk found in the ear

Thyroid cancer is a rare type of cancer affecting the thyroid gland which is a small gland at the base of the neck producing hormones. Women are two to three times more likely to develop it than men. Having this sensation in your ear could indicate your risk of the disease.

It’s not usually clear what causes thyroid cells to grow uncontrollably but there are a number of things that can increase your risk.

It is important to note that having any of the risk factors doesn’t mean that you will definitely develop cancer.

According to Cancer Research UK, some non-cancerous (benign) conditions of the thyroid increase your risk of thyroid cancer.

These include:

Nodules (adenomas)

An enlarged thyroid (goitre)

Inflammation of the thyroid (thyroiditis).

“Thyroid cancer is more common in people who had radiotherapy treatment, particularly in people treated with radiotherapy when they were children,” warns Cancer Research UK.

See a GP if you have symptoms of thyroid cancer, warns the NHS.

The national health body added: “The symptoms may be caused by less serious conditions, such as an enlarged thyroid, so it’s important to get them checked.

“A GP will examine your neck and can organise a blood test to check how well your thyroid is working.

“If they think you could have cancer or they’re not sure what’s causing your symptoms, you’ll be referred to a hospital specialist for more tests.”

This post originally appeared on Daily Express :: Health Feed
Read More

Cancer symptoms: Expert uncovers five key signs of a growing thyroid tumour

Cancer symptoms: Expert uncovers five key signs of a growing thyroid tumour

Speaking exclusively to Express.co.uk is Mr Jean-Pierre Jeannon, a Consultant ENT (Ears, Throat and Nose) Surgeon at London Bridge Hospital (part of HCA UK) and Guy’s & St Thomas’s NHS Hospital. “Patients with thyroid cancer usually have normal thyroid function blood tests,” cautioned Dr Jeannon. Thus, people need to be aware of the physical manifestations of the tumour.

However, “if it persists for more than three weeks and grows worse over time”, he recommends visiting your GP to get it checked out. “It can be a sign of thyroid cancer,” he warned.

Unexplained hoarseness might also be a sign of a growing tumour, but it can also be a sign of a bacterial infection.

“If it is persistent and does not go away after three weeks, seek help from your GP,” instructed Dr Jeannon.

One more possible sign of thyroid cancer is “difficult or noisy breathing”.

Papillary Thyroid Cancer (PTC)

This is the most common type of thyroid cancer, Dr Jeannon explained, and has “the best prognosis”.

“Over 90 percent of patients with this type of cancer survive,” he revealed.

Follicular Thyroid Cancer (FTC)

This type of thyroid cancer is less common; it’s treated in the same way that PTC is addressed – by a “total thyroidectomy surgery followed by radio-iodine therapy for the more advanced cases”.

Medullary Thyroid Cancer (MTC)

MCT “is a rare form often associated with an inherited condition called multiple endocrine neoplasia (MEN)”.

To treat MEN, the lymph nodes and the thyroid gland are usually removed during surgery.

Anaplastic Thyroid Cancer (ATC)

ATC is “very rare” and has the “worst prognosis”, usually progressing to fatality.

“Treatment for this rare cancer is palliative chemotherapy,” said Dr Jeannon.

This post originally appeared on Daily Express :: Health Feed
Read More

Even Inactive Thyroid Eye Disease Adversely Impacts Patients

Even Inactive Thyroid Eye Disease Adversely Impacts Patients

Ocular signs and symptoms of thyroid eye disease (TED) often persist beyond the active phase of the condition, with many patients continuing to experience mental health issues and diminished quality of life, new research suggests.

The autoimmune condition TED involves orbital inflammation with subsequent proptosis (eye bulging), diplopia, corneal exposure, vision changes, and potential blindness. The initial acute progressive phase of active inflammation lasts between 1 and 3 years. Inflammation then typically subsides, but patients can still experience chronic sequelae including ocular pain and discomfort, vision disturbance, and facial disfigurement.

Findings from a cross-sectional survey comparing about 300 patients with active or inactive TED were presented May 29 at the American Association of Clinical Endocrinology (AACE) Virtual Annual Meeting 2021 by Lissa Padnick-Silver, PhD, senior manager of medical affairs at Horizon Therapeutics, Deerfield, Illinois.

“Chronic TED is generally thought of as inactive and stable, but the persistence of ocular signs/symptoms, mental health issues, and long-term impairment of patient quality of life make TED seem anything but ‘inactive,’ especially to the patient,” Padnick-Silver said.

Horizon makes the monoclonal antibody teprotumumab (Tepezza), which was approved by the US Food and Drug Administration in January 2020 for the treatment of adults with TED. The survey was conducted in 2018 prior to the drug’s approval.  

Asked to comment, session moderator Jad G. Sfeir, MD, of the Mayo Clinic, Rochester, Minnesota, told Medscape Medical News: “Many of us assume that once the eye disease is inactive it shouldn’t be causing any trouble in the background anymore. However, we see now that there is a good proportion [of patients] who continue to have depression and other mental health and psychosocial effects that will impact them. This type of study will enlighten physicians definitely to ask more about these with the hope that we can offer some help to these patients.”

However, Sfeir noted that the study did not provide any guidance on how to treat the problem. “The biggest issue, of course, is what to do to help, and whether the new drug that has been on the market for a little over a year now will make a difference in terms of quality of life, and whether it will have any impact even after the disease goes inactive and you stop the medication. Will that change the quality of life in the inactive disease that was treated? We just need to wait for long-term data to be able to answer this question.”

Sfeir also cautioned about over-interpreting the data, particularly those concerning rates of reported anxiety and depression, given the cross-sectional nature of the study.

Mental Health Impact of Inactive TED Found to Be High

The study was a retrospective analysis of medical record data provided by 181 US physicians — endocrinologists and ophthalmologists — for a total of 714 patients who had moderate-to-severe TED. Of those, 281 patients (39%) had active TED defined as a clinical activity score (CAS) of 3 or greater, and 307 patients (43%) had inactive TED, defined as a CAS of 0 or 1. The rest, with CAS 2, were not included in the analysis.   

About two thirds of both groups were women, with a mean age of around 50 years. The group with inactive TED was diagnosed at a slightly younger age (43.8 vs 46.1 years; P = .031). At the time of the survey, the proportions with severe TED were 5% with inactive disease versus 25% with active TED (P < .001). The mean CAS was 0.5 for those with inactive TED versus 4.1 for active TED (P < .001). There were no significant differences in thyroid status, smoking status, or TED duration.

Ocular dryness/grittiness was the most common ocular symptom in both groups, reported by 77% with inactive TED and 92% with active TED.

For those with inactive TED, the next most commonly listed ocular symptoms were proptosis in 56%, excessive tearing in 43%, and soft-tissue edema in 42%.

That list contrasts somewhat from the active TED group, in whom the next three most common symptoms were soft-tissue edema in 92%, conjunctival redness in 90%, and proptosis in 78%. Decreased vision was reported by 24% with inactive TED, compared to 63% with active TED.

Mental health issues were reported by 37% with active TED and 36% with inactive TED, not significantly different from each other but significantly higher than the 19% seen in the general US adult population, as reported by the National Institute of Mental Health in 2017, Padnick-Silver said.

Specifically, anxiety was reported in 28% with active TED and 26% with inactive TED, compared with 19% in the general US population. Depression was reported in 19% and 17% versus 7%, respectively.

Regarding the mental health statistics, Sfeir said that although it’s somewhat surprising that more than a third with inactive disease reported having anxiety and/or depression, at the same time, “it’s a cross-sectional survey, so hard to know what it means. Their background may be different. Some may have had active disease before and some not. Also, we don’t know the status of their thyroid treatment or whether they have other autoimmune diseases. We need a bit more information to make good sense of these data.”

Quality of Life Also Affected

Physicians also rated the impact of TED on the patients’ quality of life using a seven-point Likert scale, with one being not at all impaired and seven being extremely impaired.

Overall, those with inactive TED were given a score of 3.6, and those with active TED, 4.7. For all the subscales — work/school, social, daily activities, driving, and psychological well-being — all scores were 3.1 or greater for inactive TED and 4.1 or greater for active TED. Psychological well-being was most affected in the inactive TED and active TED groups (3.6 and 4.6).

“These findings agree with a previous study of mostly moderate-to-severe TED patients, which showed that some psychologically adapt to appearance changes and functional limitations associated with TED,” Padnick-Silver commented.

The 281 patients with inactive TED were divided into 166 with short-term TED (duration 3 years or less) and 115 with long-term TED (more than 3 years). Reported TED signs and symptoms were similar between the two groups, except for ocular dryness/grittiness, which was more prevalent in the long-term TED group (85% vs 72%; P = .009).

Quality of life scores were also similar between the groups (3.4 vs 3.7; P = .073), and the prevalence of mental health issues — anxiety and/or depression — was identical, at 36% for both.  

During the question-and-answer period, Sfeir asked Padnick-Silver whether there were plans to repeat the study now that teprotumumab, the first disease-modifying treatment for TED, is available.

She replied, “It would be a wonderful thing; it’s certainly in talks. There are no active plans to do that, but it is definitely something we’re interested in.”  

The study was funded by Horizon. Padnick-Silver is a Horizon employee and stockholder. Sfeir has reported no relevant financial relationships.

AACE Virtual Annual Meeting 2021. Presented May 29, 2021.

Miriam E. Tucker is a freelance journalist based in the Washington, DC, area. She is a regular contributor to Medscape, with other work appearing in The Washington Post, NPR’s Shots blog, and Diabetes Forecast magazine. She is on Twitter: @MiriamETucker.

For more diabetes and endocrinology news, follow us on Twitter and Facebook.

This post originally appeared on Medscape Medical News Headlines

Love Island star Demi Jones, 21, diagnosed with thyroid cancer after noticing lump on neck

Love Island star Demi Jones, 21, diagnosed with thyroid cancer after noticing lump on neck

Demi later told fans to “chase it up” if appointments get cancelled as she was due to have her check-up six months prior to the date she visited the hospital.

She said: “At my scan, they said, ‘Everything looks fine’ and went to send me on my way. I challenged it and asked if they could do more, in which they said, ‘Oh well we can test the fluid if you want us to?'”

The reality star later added: “Thank god I asked as it was the fluid that can be potentially cancerous. Always push!”

There are four main types of Thyroid cancer including papillary carcinoma, follicular carcinoma, medullary thyroid carcinoma, anaplastic thyroid carcinoma.

Symptoms of Thyroid cancer include a painless lump or swelling in the front of the neck, swollen glands, unexplained hoarseness, a sore throat and difficulty swallowing, according to the NHS.

This post originally appeared on Daily Express :: Celebrity News Feed

Some NP Thyroid Lots Recalled Due to Reduced Potency

Some NP Thyroid Lots Recalled Due to Reduced Potency

In its third voluntary recall in the past year, Acella Pharmaceuticals has announced a nationwide recall of specific lots of its popular hypothyroid treatment NP Thyroid tablets USP, this time after routine testing found the pills to be subpotent.

Specifically, the affected lots were found to contain less than 90% of the drug’s two labeled ingredients to treat hypothyroidism: liothyronine (LT3) and/or levothyroxine (LT4).

The affected lots include 15-mg, 30-mg, 60-mg, 90-mg and 120-mg formulations of NP Thyroid tablets, packed in 100-count and 7-count bottles.

The list of the specific recalled lots is published on the Food and Drug Administration website.

Acella reports that, so far, 43 reports of serious adverse events that could be related to the recall have been received.

Symptoms suggesting patients may have received a subpotent batch include the common signs of hypothyroidism, such as fatigue, increased sensitivity to cold, constipation, dry skin, puffy face, hair loss, slow heart rate, depression, swelling of the thyroid gland and/or unexplained weight gain or difficulty losing weight, Acella reports.

“There is reasonable risk of serious injury in newborn infants or pregnant women with hypothyroidism including early miscarriage, fetal hyperthyroidism, and/or impairments to fetal neural and skeletal development,” the company cautions in the recall statement.

Acella adds that toxic cardiac manifestations of hyperthyroidism, including cardiac pain, palpitations or cardiac arrhythmia may occur in elderly patients and patients with underlying cardiac disease.

While Acella is notifying affected parties to discontinue distribution of the recalled products, it advises that patients who are currently taking NP Thyroid from the lots being recalled “should not discontinue use without contacting their healthcare provider for further guidance and/or a replacement prescription.”

In November 2020, a recall of NP Thyroid was issued after FDA testing found subpotent levels, as low as 87% of the labeled amount, of LT4 in some lots.

And earlier, in May 2020, the company recalled 13 lots of the tablets due to excessive potency, with FDA testing showing some tablets contained up to 115% of the labeled amount of LT3.

NP Thyroid is a type of desiccated animal thyroid product that was long the standard of care for hypothyroidism prior to the advent of the synthetic hypothyroidism drug, Synthroid (levothyroxine sodium), now the most commonly used hypothyroidism treatment.

On its website, Acella refers to NP Thyroid as a “natural choice for thyroid therapy,” as desiccated thyroid is commonly referred to.

However, one of the most common concerns about desiccated thyroid is a tendency to have unreliable concentrations of active ingredients, as discussed in American Thyroid Association recommendations.

The “amounts of both T4 and T3 can vary in every batch of desiccated thyroid, making it harder to keep blood levels right,” the ATA states.

“Finally, even desiccated thyroid pills have chemicals (binders) in them to hold the pill together, so they are not completely ‘natural.’ ”

Consumers with questions about the recall are advised to email Acella Pharmaceuticals at [email protected] or call 1-888-424-4341, Monday through Friday from 8:00 am to 5:00 pm ET.

This article originally appeared on MDedge.com, part of the Medscape Professional Network.

This post originally appeared on Medscape Medical News Headlines

Chris Kamara diagnosed with underactive thyroid after undergoing scan for ‘brain fog’

Chris Kamara diagnosed with underactive thyroid after undergoing scan for ‘brain fog’

Chris and host Steph were later joined by Doctor Pete Taylor, who discussed possible symptoms of an underactive thyroid.

The doctor said the condition was usually something that develops slowly and urged people who might be concerned to seek help from a GP.

“I have to say I’m embarrassed about it, so I ignore it,” the Sky Sports regular admitted.

“Even though other people might mention it, I go, ‘Oh no, I’m fine’.”

Steph’s Packed Lunch airs weekdays from 12.30pm on Channel 4.

This article originally appeared on Daily Express :: Celebrity News Feed